...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing
【24h】

Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing

机译:要点:一次治疗一对碱基对人类遗传病:基因编辑的好处

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The observation that the human genome can be mapped represented a major inflection point in biology. The decision to sequence the human genome was met with excitement and trepidation. The arguments for and against sequencing included whether the technology was sufficiently advanced, whether it would divert resources from elsewhere, and whether it could have unknown negative societal benefits. Some 2 decades later, the delivery of the first draft of the human genome was received as a crowning achievement of science. Now, high-throughput genomic technologies have potentiated mutation discovery across many disorders and have carried with them the promise that treatments for these ailments will eventually follow. Indeed, terminology such as a??individualized medicine,a?? a??precision medicine,a?? a??personalized medicine,a?? and other similar terms abound, and these imply that by reading the genome; integrating worldwide data sets with clinical observation; and real-time biometric readings, diagnosis will be expedited and treatments will be tailored to the needs of each individual genome. Reflecting on the genome journey, there is no question that giant advances in diagnostics and therapy have been made. We celebrated gene therapy trials such as Ashanti DeSilva's to treat adenosine deaminase deficiency in 1990 (1) and some forms of retinal degeneration (2). We cheered when enzyme replacement therapy and allogeneic stem cell transplants showed some effectiveness in catastrophic inborn errors of metabolism (3) such as Pompe disease, and, as RNA therapeutics emerged, we marveled at the early successes of antisense oligonucleotides delivered intrathecally to treat spinal muscular atrophy (4), to name but a few exemplars. Unfortunately, these successes represent a handful of a??solutionsa?? in the backdrop of 10000+ rare and ultrarare genetic diseases (https://rarediseases.org/). Under current paradigms it is difficult to see a path to more a?|
机译:人类基因组可以作图的观察代表了生物学中的一个主要拐点。对人类基因组测序的决定引起了激动和恐惧。支持和反对测序的论点包括该技术是否足够先进,是否会从其他地方转移资源以及它是否可能具有未知的负面社会利益。大约20年后,人类基因组第一稿的交付获得了科学的最高成就。现在,高通量基因组技术已增强了许多疾病的突变发现,并带来了有望最终解决这些疾病的承诺。确实,诸如“个体化医学”之类的术语?一个??精密药物,一个??一种个性化药物,一种其他类似的术语比比皆是,这意味着通过阅读基因组;将全球数据集与临床观察相结合;和实时生物特征读数,将加快诊断速度,并根据每个个体基因组的需要量身定制治疗方案。反思基因组的历程,毫无疑问,诊断和治疗取得了巨大的进步。我们在1990年庆祝了基因疗法试验,例如Ashanti DeSilva's治疗腺苷脱氨酶缺乏症(1)和某些形式的视网膜变性(2)。当酶替代疗法和同种异体干细胞移植对庞贝氏病等严重的先天性代谢失误(3)表现出某些功效时,我们感到高兴,并且,随着RNA疗法的兴起,我们为鞘内注射用于治疗脊髓性肌病的反义寡核苷酸的早期成功感到惊讶萎缩(4),仅举几个例子。不幸的是,这些成功代表了少数解决方案。在10000多种罕见和极少见的遗传疾病的背景下(https://rarediseases.org/)。在当前的范式下,很难找到一条通往更多?

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号